Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest update is out from Hansoh Pharmaceutical Group Company Limited ( (HK:3692) ).
Hansoh Pharmaceutical Group announced that its partner GlaxoSmithKline (GSK) has received the FDA Breakthrough Therapy Designation for HS-20093, a B7-H3-targeted antibody-drug conjugate, for treating relapsed or refractory osteosarcoma. This designation marks a significant milestone in the development of HS-20093, potentially strengthening Hansoh’s position in the pharmaceutical industry and enhancing its market reach through innovative cancer therapies.
More about Hansoh Pharmaceutical Group Company Limited
Hansoh Pharmaceutical Group Company Limited is a company incorporated in the Cayman Islands, focusing on the development and commercialization of innovative drugs, particularly in oncology, central nervous system disorders, and infectious diseases.
YTD Price Performance: -3.59%
Average Trading Volume: 8,235,389
Technical Sentiment Consensus Rating: Hold
Current Market Cap: HK$98.89B
See more insights into 3692 stock on TipRanks’ Stock Analysis page.